The cranial mesenchyme undergoes dramatic morphogenic movements that likely provides a driving force for elevation of the neural folds1,2. Here we describe a simple ex vivo explant assay to characterize the cellular behaviors of the cranial mesenchyme during neurulation. This assay has numerous applications including being amenable to pharmacological manipulations and live imaging analyses.
The central nervous system is derived from the neural plate that undergoes a series of complex morphogenetic movements resulting in formation of the neural tube in a process known as neurulation. During neurulation, morphogenesis of the mesenchyme that underlies the neural plate is believed to drive neural fold elevation. The cranial mesenchyme is comprised of the paraxial mesoderm and neural crest cells. The cells of the cranial mesenchyme form a pourous meshwork composed of stellate shaped cells and intermingling extracellular matrix (ECM) strands that support the neural folds. During neurulation, the cranial mesenchyme undergoes stereotypical rearrangements resulting in its expansion and these movements are believed to provide a driving force for neural fold elevation. However, the pathways and cellular behaviors that drive cranial mesenchyme morphogenesis remain poorly studied. Interactions between the ECM and the cells of the cranial mesenchyme underly these cell behaviors. Here we describe a simple ex vivo explant assay devised to characterize the behaviors of these cells. This assay is amendable to pharmacological manipulations to dissect the signaling pathways involved and live imaging analyses to further characterize the behavior of these cells. We present a representative experiment demonstrating the utility of this assay in characterizing the migratory properties of the cranial mesenchyme on a variety of ECM components.
Neural tube closure in the cranial region occurs between embryonic day 8.5 (E8.5) and 9.5 in the mouse embryo. Failure to properly close the neural tube in the head results in anencephaly, a common structural birth defect in humans and is incompatible with life. The forces that drive cephalic neural tube closure are generated from both the neural tissue itself and the surrounding epidermis and mesenchyme3. In particular expansion of the cranial mesenchyme is thought to be essential for elevation of the cranial neural folds1,2. The cranial mesenchyme is rich in ECM proteins in particular glycosylated proteins such as heparin sulphate proteoglycans, chondroitin sulfates and hyaluronate4-8.
Unlike in the chicken embryo where neural crest cells emigrate from the dorsal neural tube following neural tube closure, the neural crest in the mouse embryo migrates at the same time that the neural folds begin to rise (after the 5 somite stage). Thus during neurulation in the mouse embryo, the cranial mesenchyme is composed of cells derived from the neural crest and the paraxial mesoderm. Neural crest and paraxial mesoderm populations are induced at different times in development; localized in different positions in the embryo and develop into different structures9,10. The paraxial mesoderm originates from the primitive streak and migrates to the anterior region of the embryo to underlie the presumptive neural plate. The neural crest is induced at the junction of the neural plate and epidermal ectoderm, undergoes an epithelial to mesenchyme transition and delaminates just prior to neural fold elevation in the rodent embryo. Neural crest cells migrate along stereotypic paths in the subectodermal paraxial mesoderm to the branchial arch, frontonasal and periocular mesenchyme. The paraxial mesoderm will contribute to some of the bones of the skull vault and muscles of the face; whereas the neural crest will contribute to other bones of the skull and face in addition to cranial nerves9-11. The paraxial mesoderm and neural crest lineages can be differentially marked by the Mesp1-cre and Wnt1-cre transgenic mouse lines, respectively 9.
The essential role of the cranial mesenchyme in neural tube closure has been inferred from experiments where treatment of rodent embryos with ECM disrupting agents such as hyaluronidase, chondroitinase ABC, heparitinase or Diazo-oxo-norleucine (DON) during neurulation impaired neural tube closure7,12-14. In these experiments, histological analysis of static sections following neurulation revealed associated dysmorphogeneis of the cranial mesenchyme7,12-14. However, since the teratogenic agent had access to multiple tissues, it remains to be determined if the cranial mesenchyme is really the target tissue. In support of the conclusion that this tissue is essential for neurulation, the cranial mesenchyme appears abnormal upon histological analyses in some mouse mutants with exencephaly15-17. Still, in most cases, the effect of the mutation on the cellular behavior of the cranial mesenchyme has not been addressed.
We have devised an ex vivo explant assay to directly examine the consequence of genetic mutation or pharmacological manipulation on the behavior of cranial mesenchyme cells15. This assay is similar to that published by Tzahor et al 2003 to access the differentiation potential of the cranial mesenchyme that underlies the rhombomeres18 except we have modified the explant dissection to study the migratory properties of more anterior populations of cranial mesenchyme that underlie the anterior neural plate. Our method is also a modification of explant assays performed in the chicken embryo to analyze the migratory behavior of the neural crest with key differences. Previous preparations have explanted the neural crest or the more posterior paraxial mesoderm19,20. Furthermore, during neural fold elevation in the chicken embryo, the neural crest has not yet emigrated from the dorsal neural tube and thus explants taken of the anterior paraxial mesoderm would not contain neural crest cells. In our assay, cranial mesenchyme explants consisting of paraxial mesoderm, neural crest and surface ectoderm are prepared and plated on a substrate. Experimental manipulation including isolation of explants from genetic mutants, plating explants on different ECM or pharmacological treatments can be performed. Cells migrate from the explant and the distance, number and behavior can be analyzed and compared between treatment groups. In addition, this preparation is amendable to analyses of cellular migration by live imaging techniques. After the migration experiment, explants can be fixed and subjected to immunohistochemical analyses to further elucidate the effect of treatments. On the whole, the protocol presented here is a simple ex vivo assay to investigate the behavior of the cranial mesenchyme. As a representative experiment, we utilize this assay to examine the migration of cranial mesenchyme on different extracellular substrates.
1. Preparation of ECM Coated Culture Dishes or Coverslips
2. Preparation of Dissection Tools
Sylgard plates with added charcoal are prepared per the manufacture’s protocol. The resistant black background of these plates provides support for pinning down the embryo and the color offers good contrast which facilitates visualizing the translucent embryo.
3. Collection of Embryos
4. Preparation of Explants
Critical steps in the protocol
Troubleshooting
The appearance of cells migrating from cranial mesenchyme explants is shown in Figure 2. We tested migration on various ECM substrates that are present in the cranial mesenchyme during neurulation including Fibronectin (100 mg/ml; Sigma #F1141), Laminin (100 mg/ml; Sigma #L2020), MaxGel ECM (1:500 dilution in DMEM; Sigma #E0282) and Hyaluronic acid (1 mg/ml; Sigma, # 53747). Cells fail to migrate from the explant when no ECM is present (Data not shown) and all substrates tested supported migration of the cells. Both the shape as well as the sizes of cells that migrate from the explants depends upon the substrate. This is expected as previous studies demonstrate that the mechanical forces generated by interaction of cells with different ECM affect both the shape and migratory properties of cells21.
Figure 1. Preparation of explants. (A) To prepare explants, E8.5 embryos are dissected from deciduas and extraembryonic tissues. (B) Embryo heads are dissected from the body anterior to the rhombomeres. Explants are prepared by removing tissue from the midline and the outer edges of the head to remove the prechordal plate at the midline and the premigratory neural crest and surface ectoderm at the border, respectively. (C) Explants are prepared by cutting away tissue from the midline and outer edges of the head to remove the prechordal plate at the midline and the premigratory neural crest and surface ectoderm at the borders. (D) Explants are placed in a small volume of media on ECM coated dishes/coverslips and allowed to attach before the addition of more media.
Figure 2. Migration of cranial mesenchyme cells from explants plated on different substrates. Explants were plated on Fibronectin, Laminin, MaxGel ECM or Hyaluronic acid and photographed after 48 hr in culture. Size bar = 200 mm.
The method applied here provides a powerful assay to examine the behavior of cranial mesenchyme cells. In addition to the static analyses presented here, live imaging experiments in bright field or in combination with expression of GFP-labeled proteins can be employed to examine the behaviors of cells in real time as they migrate from the explant. For live imaging experiments, explants could be labeled with DiI or to differentiate migration of neural crest from the paraxial mesoderm, ROSA-YFP;Mesp1-cre or ROSA-YFP;Wnt1-cre or other transgenic lines could be used. Cranial mesenchyme-ECM interactions can also be examined utilizing this explant assay. Here we plate explants on different ECM substrates that are present in the cranial mesenchyme to show that cells migrate on these to different degrees and that the ECM influences the morphology of the cells. Furthermore, explants can be embedded in a three-dimensional matrix to access the behaviors of cells in this context. This explant assay is amendable to analysis of the effect of genetic and pharmacological manipulations on cranial mesenchyme behaviors to analyze intrinsic and extrinsic cues that can regulate and modify migration. For example, we utilized this assay in our studies to discern the role of excess Hsp90 secretion in the abnormal cellular behaviors in Hectd1 mutant cranial mesenchyme15. In these experiments, we treated explants with anti-Hsp90 antibody, Hsp90 protein, geldanamycin and DMA (dimethyl amelioride) to block secretion of Hsp90 to demonstrate that the abnormal behavior of Hectd1 mutant cells is due to excess extracellular Hsp9015. Similar approaches could be used to pharmacologically dissect additional pathways underlying normal or abnormal morphogenesis of the cranial mesenchyme. Once the assay is completed, explants and migrating cells can be analyzed by a host of methods. For example, immunohistochemical analyses can be employed to examine localization of proteins critical for cell movements. Transcriptome analyses could also be employed to determine how treatments affect gene expression.
One significant limitation of this technique is that it does not model behaviors in three-dimensions as they would occur in vivo. Modification of the protocol where explants are embedded in a three-dimensional matrix (e.g. matrigel) along with expression of fluorescent protein-marked cellular compartments could be employed necessary to address this issue. Even if these modifications were performed, further experiments to correlate behaviors seen in this ex vivo assay with those in vivo would be necessary. Other limitations include the large number of embryos required to generate sufficient numbers to generate statically significant data. Most importantly, the dissection is relatively simple, it does require practice to master.
The authors have nothing to disclose.
This work is supported by R01-HD058629 to I.E.Z.